Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination

• Published in: Vaccine 2015-03, Vol.33 (14), p.1719-1725
• Main Authors: Wysocki, Jacek, Brzostek, Jerzy, Szymański, Henryk, Tetiurka, Bogusław, Toporowska-Kowalska, Ewa, Wasowska-Królikowska, Krystyna, Sarkozy, Denise A, Giardina, Peter C, Gruber, William C, Emini, Emilio A, Scott, Daniel A
• Format: Article
• Language: English
• Subjects: Age; Allergy and Immunology; Antibodies, Bacterial - blood; Child; Child, Preschool; Female; Healthy Volunteers; Humans; Immune response; Immunization; Immunogenicity; Immunoglobulin G - blood; Infant; Infants; Male; Meningitis; Mortality; Pneumococcal conjugate vaccine; Pneumococcal Infections - prevention & control; Pneumococcal Vaccines - administration & dosage; Pneumococcal Vaccines - adverse effects; Pneumococcal Vaccines - immunology; Pneumonia; Poland; Safety; Statistical analysis; Streptococcus infections; Streptococcus pneumoniae; Streptococcus pneumoniae - immunology; Vaccine clinical evaluation; Vaccines; Vaccines, Conjugate - administration & dosage; Vaccines, Conjugate - adverse effects; Vaccines, Conjugate - immunology
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2015.02.005

Highlights • Some children may not receive pneumococcal conjugate vaccine (PCV) as infants. • PCV13 was evaluated in pneumococcal vaccine-naïve children aged 7 months to 5 years. • Age-specific “catch-up” vaccination schedules were evaluated. • The proportion of immunological responders ranged from 88% to 100% for all 13 serotypes. • PCV13 was generally well-tolerated; trend for greater tenderness in older subjects.